1-8 of 8
Ann M. Kapoun
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

Niharika B. Mettu, Susanna V. Ulahannan, Johanna C. Bendell, Ignacio Garrido-Laguna, John H. Strickler, Kathleen N. Moore, Robert Stagg, Ann M. Kapoun, Leonardo Faoro, Sunil Sharma
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 882–892.
https://doi.org/10.1158/1078-0432.CCR-21-2780
Published: 03 March 2022
View article titled, A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
Open the PDF for A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer

Efrat Dotan, Dana B. Cardin, Heinz-Josef Lenz, Wells Messersmith, Bert O'Neil, Steven J. Cohen, Crystal S. Denlinger, Safi Shahda, Igor Astsaturov, Ann M. Kapoun, Rainer K. Brachmann, Shailaja Uttamsingh, Robert J. Stagg, Colin Weekes
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5348–5357.
https://doi.org/10.1158/1078-0432.CCR-20-0489
Published: 15 October 2020
View article titled, Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer
Open the PDF for Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer in another window
Journal Articles

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

Antonio Jimeno, Michael Gordon, Rashmi Chugh, Wells Messersmith, David Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Shailaja Uttamsingh, Rainer K. Brachmann, David C. Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7490–7497.
https://doi.org/10.1158/1078-0432.CCR-17-2157
Published: 14 December 2017
View article titled, A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors in another window
Journal Articles

Abstract A42: Using a PDX tumor bank to screen for cancer stem cell therapies

James Evans, Chun Zhang, Angie InKyung Park, Alayne Brunner, Min Wang, Cristina Dee-Hoskins, Roger Lopez, Xiaomei Song, Kellie Pickell, Wan-Cheng Yen, Marcus Fischer, Raymond Tam, Gilbert O'Young, Jakob Dupont, Lei Zhou, Austin Gurney, John Lewicki, Tim Hoey, Ann M. Kapoun, Belinda Cancilla
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): A42.
https://doi.org/10.1158/1557-3265.PDX16-A42
Published: 15 August 2016
View article titled, Abstract A42: Using a PDX tumor bank to screen for cancer stem cell therapies
Journal Articles

Abstract A29: Discovery and preclinical to clinical evaluation of biomarkers for Anti-DLL4, a monoclonal antibody targeting cancer stem cells

Ann M. Kapoun, Min Wang, Gilbert O'Young, Lucia Beviglia, Yu-Wang Liu, Pete Yeung, Marcus Fischer, Dave Smith, John Lewicki, Tim Hoey
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): A29.
https://doi.org/10.1158/1078-0432.TCMUSA10-A29
Published: 02 February 2016
View article titled, Abstract A29: Discovery and preclinical to clinical evaluation of biomarkers for Anti-DLL4, a monoclonal antibody targeting cancer stem cells
Journal Articles

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

Wan-Ching Yen, Marcus M. Fischer, Fumiko Axelrod, Christopher Bond, Jennifer Cain, Belinda Cancilla, William R. Henner, Rene Meisner, Aaron Sato, Jalpa Shah, Tracy Tang, Breanna Wallace, Min Wang, Chun Zhang, Ann M. Kapoun, John Lewicki, Austin Gurney, Timothy Hoey
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (9): 2084–2095.
https://doi.org/10.1158/1078-0432.CCR-14-2808
Published: 30 April 2015
View article titled, Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Open the PDF for Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency in another window
Includes: Supplementary data
Journal Articles

A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

David C. Smith, Peter D. Eisenberg, Georgy Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert J. Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, Branimir Sikic
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (24): 6295–6303.
https://doi.org/10.1158/1078-0432.CCR-14-1373
Published: 14 December 2014
View article titled, A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
Open the PDF for A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells

Wan-Ching Yen, Marcus M. Fischer, Mark Hynes, Jingjiang Wu, Edward Kim, Lucia Beviglia, V. Pete Yeung, Xiaomei Song, Ann M. Kapoun, John Lewicki, Austin Gurney, Diane M. Simeone, Timothy Hoey
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5374–5386.
https://doi.org/10.1158/1078-0432.CCR-12-0736
Published: 30 September 2012
View article titled, Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
Open the PDF for Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells in another window
Includes: Supplementary data